India, March 25 -- CorMedix Inc. (CRMD), a biopharmaceutical company, on Tuesday announced a turnaround to profit in the fourth quarter from loss in the last year. The company recorded revenue for the quarter on sales of DefenCath and reiterated cash operating expenses for the full year.
Shares of CorMedix are dropping in the pre-market trading.
In the fourth quarter, net income came in at $13.47 million compared with net loss of $14.75 million last year.
Fourth quarter earnings per share were $0.22 versus loss of $0.26 the prior year.
Five Analysts, on average, had expected the company to report $0.14 per share. Analysts' estimates typically exclude special items.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-156818950...